Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295621 | 1.00 | HTR1A (0.43) | HTR1AHTR2CSLC6A2HTR2BSIGMAR1 | |
| SCHEMBL28705121 | 0.92 | HCRTR2 (0.40) | HTR1AHTR2CSLC6A2HTR2BSIGMAR1 | |
| SCHEMBL12362004 | 0.86 | FFAR1 (0.47) | FFAR1PPARGPPARDCYP19A1CA2 | |
| SCHEMBL13981216 | 0.84 | HTR1A (0.51) | HTR1AHTR2CSLC6A2HTR2BSIGMAR1 | |
| SCHEMBL27347334 | 0.82 | FFAR1 (0.60) | FFAR1PPARGPPARD | |
| SCHEMBL27347336 | 0.82 | FFAR1 (0.60) | FFAR1PPARGPPARD | |
| SCHEMBL27347333 | 0.82 | FFAR1 (0.60) | FFAR1PPARGPPARD | |
| SCHEMBL95790 | 0.80 | HTR2C (0.61) | HTR1AHTR2CSLC6A2HTR2BSIGMAR1 | |
| SCHEMBL30485736 | 0.79 | MAOB (0.46) | HTR1AHTR2CHTR1DFFAR1PPARG | |
| SCHEMBL21056035 | 0.79 | MAOB (0.46) | HTR1AHTR2CHTR1DFFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | HTR1A 50/4885HTR2C 144/4885SLC6A2 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.